Category: Vaccine

Page 126«..1020..125126127128..140150..»

United Workers’ Job Bias Suit Over Covid Vaccine Mandate Trimmed – Bloomberg Law

December 20, 2023

United Airlines Inc. convinced a federal judge to dismiss several claims from a proposed class lawsuit over the companys handling of workers with religious or medical objections to receiving Covid-19 vaccination.

The ruling Monday by the US District Court for the Northern District of Texas rejected allegations by two of the workers leading the suit that they were denied accommodation for their religious beliefs when they were told to mask up at work and regularly submit Covid tests if they didnt want to be vaccinated. Those allegations failed to plausibly state that the workers experienced an adverse employment action, the ...

See the article here:

United Workers' Job Bias Suit Over Covid Vaccine Mandate Trimmed - Bloomberg Law

Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people … – Nature.com

December 20, 2023

World Health Organization (accessed 14 July 2023). https://covid19.who.int/.

Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 26032615 (2020).

Article CAS PubMed Google Scholar

El Sahly, H. M. et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N. Engl. J. Med. 385, 17741785 (2021).

Article CAS PubMed Google Scholar

Antonelli, M. et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect. Dis. 22, 4355 (2022).

Article CAS PubMed PubMed Central Google Scholar

Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403416 (2021).

Article CAS PubMed Google Scholar

Carazo, S. et al. Estimated protection of prior SARS-CoV-2 infection against reinfection with the Omicron variant among messenger RNAvaccinated and nonvaccinated individuals in Quebec, Canada. JAMA Netw. Open 5, e2236670 (2022).

Article PubMed PubMed Central Google Scholar

Connors, J., Bell, M. R., Marcy, J., Kutzler, M. & Haddad, E. K. The impact of immuno-aging on SARS-CoV-2 vaccine development. Geroscience 43, 3151 (2021).

Article CAS PubMed PubMed Central Google Scholar

Soiza, R. L., Scicluna, C. & Thomson, E. C. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing 50, 279283 (2021).

Article PubMed Google Scholar

Lynn, D. J. & Pulendran, B. The potential of the microbiota to influence vaccine responses. J. Leukoc. Biol. 103, 225231 (2018).

Article CAS PubMed Google Scholar

McDermott, A. J. & Huffnagle, G. B. The microbiome and regulation of mucosal immunity. Immunology 142, 2431 (2014).

Article CAS PubMed PubMed Central Google Scholar

Baradaran Ghavami, S. et al. Cross-talk between immune system and microbiota in COVID-19. Expert Rev. Gastroenterol. Hepatol. 15, 12811294 (2021).

Article CAS PubMed Google Scholar

Mezouar, S. et al. Microbiome and the immune system: from a healthy steady-state to allergy associated disruption. Hum. Microbiome J. 10, 1120 (2018).

Article Google Scholar

Li, D., Breiman, A., Le Pendu, J. & Uyttendaele, M. Anti-viral effect of Bifidobacterium adolescentis against noroviruses. Front. Microbiol. 7, 864 (2016).

PubMed PubMed Central Google Scholar

Chiang, B.-L., Sheih, Y., Wang, L., Liao, C. & Gill, H. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur. J. Clin. Nutr. 54, 849855 (2000).

Article CAS PubMed Google Scholar

Gill, H. S., Rutherfurd, K. J., Cross, M. L. & Gopal, P. K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am. J. Clin. Nutr. 74, 833839 (2001).

Article CAS PubMed Google Scholar

Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337341 (2011).

Article CAS PubMed Google Scholar

Chen, J. & Vitetta, L. Inflammation-modulating effect of butyrate in the prevention of colon cancer by dietary fiber. Clin. Colorectal Cancer 17, e541e544 (2018).

Article PubMed Google Scholar

Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446450 (2013).

Article CAS PubMed Google Scholar

Lynn, D. J., Benson, S. C., Lynn, M. A. & Pulendran, B. Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nat. Rev. Immunol. 22, 3346 (2022).

Article CAS PubMed Google Scholar

Vitetta, L., Saltzman, E. T., Thomsen, M., Nikov, T. & Hall, S. Adjuvant probiotics and the intestinal microbiome: enhancing vaccines and immunotherapy outcomes. Vaccines 5, 50 (2017).

Article PubMed PubMed Central Google Scholar

Huda, M. N. et al. Stool microbiota and vaccine responses of infants. Pediatrics 134, e362e372 (2014).

Article PubMed PubMed Central Google Scholar

Harris, V. C. et al. Effect of antibiotic-mediated microbiome modulation on rotavirus vaccine immunogenicity: a human, randomized-control proof-of-concept trial. Cell Host Microbe 24, 197207.e194 (2018).

Article CAS PubMed Google Scholar

Harris, V. C. et al. Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. J. Infect. Dis. 215, 3441 (2017).

Article CAS PubMed Google Scholar

Pabst, O. & Hornef, M. Gut microbiota: a natural adjuvant for vaccination. Immunity 41, 349351 (2014).

Article CAS PubMed Google Scholar

Nakaya, H. I. et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12, 786795 (2011).

Article CAS PubMed PubMed Central Google Scholar

Oh, J. Z. et al. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity 41, 478492 (2014).

Article CAS PubMed PubMed Central Google Scholar

Kim, D. et al. Recognition of the microbiota by Nod2 contributes to the oral adjuvant activity of cholera toxin through the induction of interleukin1. Immunology 158, 219229 (2019).

Article CAS PubMed PubMed Central Google Scholar

Kim, D. et al. Nod2-mediated recognition of the microbiota is critical for mucosal adjuvant activity of cholera toxin. Nat. Med. 22, 524530 (2016).

Article CAS PubMed PubMed Central Google Scholar

Turroni, F. et al. Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl. Environ. Microbiol. 75, 15341545 (2009).

Article CAS PubMed PubMed Central Google Scholar

Koff, W. C. et al. Development and deployment of COVID-19 vaccines for those most vulnerable. Sci. Transl. Med. 13, eabd1525 (2021).

Article CAS PubMed Google Scholar

Pellini, R. et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine 36, 100928 (2021).

Article PubMed PubMed Central Google Scholar

Stefan, N., Birkenfeld, A. L. & Schulze, M. B. Global pandemics interconnectedobesity, impaired metabolic health and COVID-19. Nat. Rev. Endocrinol. 17, 135149 (2021).

Article CAS PubMed Google Scholar

Mller, L. et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin. Infect. Dis. 73, 20652072 (2021).

Article PubMed Google Scholar

Dandachi, D. et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clin. Infect. Dis. 73, e1964e1972 (2021).

Article CAS PubMed Google Scholar

Geretti, A. M. et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) clinical characterization protocol (UK): a prospective observational study. Clin. Infect. Dis. 73, e2095e2106 (2021).

Article CAS PubMed Google Scholar

Hoffmann, C. et al. Immune deficiency is a risk factor for severe COVID19 in people living with HIV. HIV Med. 22, 372378 (2021).

Article CAS PubMed Google Scholar

Chang, M. et al. Changes of gut microbiota in pregnant sows induced by 5-Aminolevulinic acid. Res. Vet. Sci. 136, 5765 (2021).

Article CAS PubMed Google Scholar

Mak, J. W. Y. Modulation of gut microbiota to enhance health and immunity (accessed 2 July 2023). https://clinicaltrials.gov/ct2/show/NCT04884776 (2020).

Falahi, S. & Kenarkoohi, A. Host factors and vaccine efficacy: implications for COVID19 vaccines. J. Med. Virol. 94, 13301335 (2022).

Article CAS PubMed Google Scholar

Chen, J., Vitetta, L., Henson, J. D. & Hall, S. The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. J. Funct. Foods 87, 104850 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zhao, T. et al. Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine. npj Vaccines 5, 47 (2020).

Article CAS PubMed PubMed Central Google Scholar

Praharaj, I. et al. Influence of nonpolio enteroviruses and the bacterial gut microbiota on oral poliovirus vaccine response: a study from South India. J. Infect. Dis. 219, 11781186 (2019).

Article CAS PubMed Google Scholar

Ichinohe, T. et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl Acad. Sci. USA. 108, 53545359 (2011).

Article CAS PubMed PubMed Central Google Scholar

Hagan, T. et al. Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. Cell 178, 13131328.e1313 (2019).

Article CAS PubMed PubMed Central Google Scholar

Wells, J. M. Immunomodulatory mechanisms of lactobacilli. Microbial Cell Factories 115 (BioMed Central, 2011).

Wexler, H. M. Bacteroides: the good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20, 593621 (2007).

Article CAS PubMed PubMed Central Google Scholar

Wright, E. K. et al. Microbial factors associated with postoperative Crohns disease recurrence. J. Crohns Colitis 11, 191203 (2017).

Article PubMed Google Scholar

Chilton, P. M., Hadel, D. M., To, T. T., Mitchell, T. C. & Darveau, R. P. Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria. Infect. Immun. 81, 33173325 (2013).

Article CAS PubMed PubMed Central Google Scholar

Fix, J. et al. Association between gut microbiome composition and rotavirus vaccine response among Nicaraguan infants. Am. J. Tropical Med. Hyg. 102, 213 (2020).

Article Google Scholar

Zafar, H. & Saier, M. H. Jr Gut Bacteroides species in health and disease. Gut Microbes 13, 1848158 (2021).

Article PubMed PubMed Central Google Scholar

Domingo, M.-C. et al. Cloacibacillus sp., a potential human pathogen associated with bacteremia in Quebec and New Brunswick. J. Clin. Microbiol. 53, 33803383 (2015).

Article PubMed PubMed Central Google Scholar

Dong, T. S. et al. Gut microbiome profiles associated with steatosis severity in metabolic associated fatty liver disease. Hepatoma Res. 7, https://doi.org/10.20517/2394-5079.2021.55 (2021).

Read more:

Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people ... - Nature.com

New COVID Shot Uptake Lagging Behind Annual Flu Shot Rates – Gallup

December 20, 2023

Story Highlights

WASHINGTON, D.C. -- Less than one-third of Americans, 29%, have gotten the new COVID-19 vaccine that was released this fall. In contrast, 47% of U.S. adults say they have gotten the annual flu shot this year.

Another 20% of U.S. adults indicate they plan to get the new COVID-19 shot, which could bring the level of current vaccination against COVID-19 to close to half of Americans, but that still falls below the combined 63% who have gotten or plan to get the flu shot.

###Embeddable###

These results are based on Gallups latest COVID-19 survey update, conducted Nov. 30-Dec. 7 with more than 6,000 adult members of Gallups probability-based panel.

Gallup had found that over seven in 10 U.S. adults had received the earlier versions of COVID-19 vaccines, which were first available to the public in late 2020 and early 2021. The past two years, booster shots to those initial vaccines were made available. The new shot can be given to people regardless of whether they have been previously vaccinated against COVID-19.

Older Americans, those aged 65 and older, are getting the updated COVID-19 shots at higher rates than the general population -- 46% have already done so. However, seniors are still more likely to have gotten the annual flu shot, with 68% saying they had.

This year, public health officials have also recommended that older Americans get vaccinated against respiratory syncytial virus, or RSV. To date, 22% of U.S. seniors have gotten an RSV vaccination.

###Embeddable###

In addition to age differences, vaccine intentions for both COVID-19 and flu differ by party identification, but more so for COVID-19.

Among the subset of U.S. adults who do not intend to receive the new COVID-19 shot, their primary reasons for not doing so are because they have had COVID-19 and believe they have antibodies (27%) and because of safety concerns about the vaccine (24%). The next most common reasons are because of questions about the effectiveness of the vaccine (18%) and because they dont believe they would suffer serious health effects from the coronavirus (16%).

Smaller proportions under 10% say they distrust vaccines in general or are concerned about an allergic reaction to the vaccine.

###Embeddable###

Forty-two percent of Democratic holdouts say they do not intend to get the new COVID-19 shot because they have had COVID-19, a much larger percentage than for independents (26%) or Republicans (20%) who dont plan to be vaccinated. Republicans who do not plan to get the COVID-19 vaccine are most likely to cite safety concerns (31%) as their primary reason.

Americans may see less of a need to get vaccinated against COVID-19 because they are less worried about getting the illness and believe the situation is improving.

Twenty-three percent of U.S. adults are very or somewhat worried about getting COVID-19, which is near the low in Gallups trend. Concern had ticked up in the prior survey, conducted in August and September, from 18% to 27% before edging down this month.

###Embeddable###

The high point in worry was measured in separate July and August 2020 surveys,when the pandemic was still in its earlier stages and before a vaccine had been developed. The low point was 17% in June 2021, when cases were declining and the vaccine was widely available.

After a less optimistic assessment of the COVID-19 situation in the August/September survey, a majority of Americans, 53%, once again see the situation as getting better. Thirty-two percent say the situation is not changing, and 15% believe it is getting worse.

Still, Americans are not as positive as they were earlier this year, when 71% thought the situation was improving.

###Embeddable###

An analysis of the data shows that Americans who are more concerned about getting COVID-19, personally, or believe the situation is worsening in the country, are more likely to have gotten vaccinated or to plan to get vaccinated.

Forty-two percent of those who are worried about getting COVID-19 have gotten the new shot, compared with 34% who are not too worried and 15% who are not worried at all. All told, 73% of those who are worried have gotten vaccinated or plan to, compared with one in four among those who are not worried at all about getting the coronavirus.

Similarly, 42% who think the COVID-19 situation is getting worse have already gotten the updated shot, compared with roughly a quarter of those who think the situation is improving or not changing.

###Embeddable###

Americans seem to be heeding public health officials recommendation to get annual flu shots to a greater degree than they are complying with their advice to get the latest COVID-19 vaccine. This may reflect lessened worry about the COVID-19 situation as it pertains to them personally and to the country more broadly. Gallup did not ask respondents about their concern with getting the flu or their assessment of the flu situation in the U.S., so it is not possible to know if greater levels of flu vaccination stem from greater worry about the flu situation than the COVID-19 situation. Greater rates of flu vaccination may reflect that that procedure is more of an established routine for Americans than getting annual COVID-19 shots.

To stay up to date with the latest Gallup News insights and updates, follow us on X.

Learn more about how the Gallup Panel works.

###Embeddable###

Follow this link:

New COVID Shot Uptake Lagging Behind Annual Flu Shot Rates - Gallup

JN.1 Covid cases: Will existing vaccines work against the new variant? Here’s what experts said – Business Today

December 20, 2023

JN.1 was first detected in the US in September 2023.

India is seeing a sudden surge in Covid-19 cases after the newest variant -- JN.1 sub-variant -- claimed four lives in Kerala. On Tuesday, the Union Health Ministry said that India has reported 260 new coronavirus infections, bringing the total COVID cases to 4.50 crore so far since the virus was detected.

In the wake of surging Covid-19 cases in the country, the government has advised states to remain vigilant in the wake of the detection of the JN.1 variant. A major question that arises following the recent surge is whether the vaccination administered before will be effective now.

JN.1 is closely related to the variant BA.2.86, says the US Centers for Disease Control and Prevention (CDC). JN.1 (also known as Pirola) was first detected in the US in September 2023.

Symptoms of JN.1 are similar to those of other coronavirus variants, including fever, runny nose, sore throat, headache, and mild gastrointestinal issues.

The CDC, in its statement, said: The continued growth of JN.1 suggests that it is either more transmissible or better at evading our immune systems. At this time, there is no evidence that JN.1 presents an increased risk to public health relative to other currently circulating variants. There is no indication of increased severity from JN.1 at this time.

Earlier experts have said JN.1 contains one additional mutation on the spike protein as compared with Pirola, which is what SARS-CoV-2 uses to latch onto patients' cells and make them sick. It was closely watched by researchers because Pirola contains more than 30 mutations on the spike protein.

In the case of India, most health experts feel that booster doses can help vulnerable patients maintain immunity over time.

As per government data, around 95 per cent citizens have received the first two doses of a Covid-19 vaccine. About a quarter have received the third or booster dose.

Dr Shailesh Sahay, Director of Internal Medicine at Max Hospital- Gurgaon, told India Today: "Vaccinations are essential for reducing the effects of Covid-19 variations, including JN.1. Boosters help the body maintain immunity over time and adjust to new strains."

Dr Sahay further said booster doses could enhance protection with a better immune response. He highlighted the significance of primary preventative measures such as mask-wearing, social distancing, and hand hygiene.

Dr Anita Mathew, Director-Internal Medicine, Fortis Hospital, Mulund, told the Economic Times: "The new variant JN1 is from the Omicron family is able to elude the immunity provided by the latest vaccine, which includes immunity against Omicron."

Dr Anurag Agarwal, a member of WHOs Technical Advisory Group on Sars-CoV-2 Virus Evolution, said: Almost everyone in India has had the infection at least two or three times so far. Most have also received at least two doses of the vaccine. This high, population-level immunity will mean that we are not likely to see the typical pneumonia-like symptoms that were seen during the first and second wave. So vaccinating to reduce the number of infections does not make sense.

What WHO said

The WHO has noted that there is no evidence that JN.1 presents an increased risk to public health relative to the other circulating variants. There is no indication of increased severity from JN.1 at this time.

WHOs technical lead Maria Van Kerkhove in a post on X elaborated on the recent surges, and what precautions can be taken. Respiratory diseases are increasing around the world due to a number of pathogens incl Covid-19, flu, rhinovirus, mycoplasma pneumonia and others. SARS-CoV-2 continues to evolve. JN.1 (sub-variant of BA.2.86) is already a VOI and continues to increase in circulation, she wrote on X.

WHO highlighted that sera from patients who had Omicron breakthrough infections (including XBB), exhibited robust neutralising activity against BA.2.86, suggesting that upcoming XBB.1.5 monovalent vaccines could confer added protection, by triggering the expansion of existing B cells that will enhance cross-protection against BA.2.86 and its descendant lineages (including JN.1). In addition, the existing Covid-19 tests and treatments are also expected to be effective against JN.1.

The Union Health Ministry has said that the existing line of treatment for Covid-19 is expected to be effective against the latest variant as well. It has not issued any special advisory on taking a booster shot.

The ministry has written to states and Union Territories asking them to monitor cases of influenza-like illnesses, conduct adequate testing, and send all positive samples for whole genome sequencing.

Also read:'Ramp-up testing, send samples for sequencing': Centre writes to states as Covid-19 variant JN.1 detected in Kerala

View post:

JN.1 Covid cases: Will existing vaccines work against the new variant? Here's what experts said - Business Today

Tropical disease found in mainland U.S., stunning physicians: ‘There’s no effective vaccine’ – Yahoo News

December 20, 2023

Its been confirmed that the mainland U.S. is now home to a disease once thought to only exist in tropical climates, as NPR has reported. Leishmaniasis has joined other diseases in spreading to new places as the warming planet opens up new populations to these diseases.

According to the World Health Organization, there are between 700,000 and one million new leishmaniasis cases a year, almost exclusively in tropical areas of the planet and, until recently, most certainly not in the contiguous United States.

But in 2014, a doctor in central Texas saw a three-year-old patient with unusual bumps on his ear who tested positive for the parasitic disease, per NPR.

I was shocked, said Bridget McIlwee, the doctor who saw the young patient, because in medical school, were taught that this is a tropical disease, something that you see in immigrants, military returning from deployment, people who went on vacation to South America or Asia or Africa.

Following that diagnosis, McIlwee and her colleagues investigated the presence of leishmaniasis in the U.S., publishing their findings in 2018. This led the Centers for Disease Control and Prevention to investigate, which reinforced those findings, suggesting that the leishmaniasis parasite has likely been present in the U.S. for years.

Leishmaniasis is primarily spread by sand flies. Most of the cases in the U.S. have been reported in Texas, but Texas is the only state that requires reporting of the disease to health authorities, so the actual spread of the disease is hard to track, NPR reported.

According to the WHO, only a small fraction of patients infected by the parasites that cause leishmaniasis will eventually develop the disease. And while there are treatments for leishmaniasis, theyre not without issues, either.

There are several [treatments], but they tend to be pretty severe and people may have side effects, Mary Kamb, a medical epidemiologist at the CDC, told NPR. And if they need to take treatment by mouth, they tend to have a long treatment period of about 28 days.

Theres no effective vaccine against leishmaniasis, and there arent any drugs that people can take to prevent it, she continued, adding that the only things that can help prevent it are wearing clothing that covers the arms and legs and, when traversing an area where there might be sand flies, using insecticide.

Leishmaniasis is the latest disease to have spread to new areas of the world as the planet continues warming. In a recent report, experts predicted that the West Nile virus, historically found in warmer regions, will travel farther and become more common than ever.

That report came on the heels of another study that showed that more areas of the planet are experiencing tropical weather, and that trend will continue.

The warmer temperatures will cause more extreme weather and population shifts, but not just among humans. Plants, mammals, and insects will also find themselves moving farther north than they would have in the past, and with them, diseases new to those areas.

The CDC is raising awareness among clinicians that leishmaniasis is now present in the U.S., despite what they may have been taught in medical school.

Every medical textbook, whether its Dermatology or Principles and Practice of Infectious Disease, teaches that this is a tropical disease, McIlwee told NPR blog Goats and Soda. So theres a huge disconnect between the clinical reality and whats being taught in medical schools.

Join our free newsletter for weekly updates on the coolest innovations improving our lives and saving our planet.

Original post:

Tropical disease found in mainland U.S., stunning physicians: 'There's no effective vaccine' - Yahoo News

Vaccine safety studies indicate serious adverse events are rare – The Washington Informer

December 20, 2023

A preprint on a Yale-based study described chronic symptoms self-reported after COVID-19 vaccination by 241 members of an online group. The paper, which has not been peer-reviewed, did not show how common these symptoms are in the general population, nor whether vaccinations caused them limitations popular online posts did not make clear.

Some peopleexperienceside effects following COVID-19 vaccination, but they are generally short-lived. There are well-established serious side effects that can occur due to COVID-19 vaccination, such asmyocarditis, but these are rare.

COVID-19 vaccinationlowersthe risk of severe disease and death from COVID-19. Among people who get COVID-19, those who are vaccinated may have areducedrisk of developing long COVID.

Apreprintof a study posted online Nov. 10 described symptoms and other characteristics of 241 members of an online group who reported that they thought the vaccine had injured them, referring to COVID-19 vaccines. The authors described this group of patients as having reported post-vaccination syndrome. Preprints are drafts of papers posted online that have not yet been peer-reviewed or published in scientific journals.

As wevewrittenpreviously, a voluntary survey cannot be used to determine whether vaccines are safe, nor can it provide a representative look at peoples experiences, positive or negative, after vaccination.

In the study, we are describing the experience of people who have a chronic syndrome that begins soon after the COVID-19 vaccination, co-authorDr. Harlan Krumholz, a cardiologist and scientist at Yale University, told us via email. Since we do not know the cause, we labeled it a post-vaccination syndrome. We described it like that because thats the timing of it.

The participants, who were predominantly white women, reported various symptoms that they believed resulted from vaccine injury, most commonly exercise intolerance, excessive fatigue, numbness, brain fog and neuropathy. They said their symptoms started a median of three days after getting vaccinated, and they filled out the survey a median of 595 days after vaccination.

Online posts may give the misleading impression that researchers have determined that the COVID-19 vaccines caused a new syndrome. Its Called Post-Vaccine Syndrome And Its Real! reads the text accompanying an episode of the Jimmy Dore Showpostedon Facebook by the shows account. Jimmy Dore, who hosts the eponymous web show, has a history of making misleading or false statements aboutvaccinationandothertopics.

To be clear, the preprint assigns the label post-vaccination syndrome to patients self-reported symptoms, but it does not establish the causes of the symptoms or their prevalence among vaccinated people.

In the episode, Dore replayed a popularvideopreviously posted on YouTube by nurse educator John Campbell, who also has ahistoryof spreading misinformation about vaccines. Campbell opened his video by welcoming his audience and saying, Researchers from Yale in the United States have identified a post-vaccine syndrome occurring after the COVID vaccinations. He did not clarify that the syndromeis a collection of symptoms that were not necessarily caused by the vaccines.

Campbell went on to give AIDS as another example of a syndrome, without stating that AIDS is now a well-characterized disease with a clear cause, while post-vaccination syndrome is a loosely defined phenomenon whose cause or causes are unclear.

He then listed percentages of participants in the study who reported each symptom, without making clear that these numbers did not mean a high proportion of all vaccinated people would experience the symptoms.

Physician-scientists who were not involved in the study emphasized what it cannot show.

We cannot draw conclusions about the causation of the symptoms reported in this study based on the study design,Dr. Linda Geng, an internal medicine doctor andco-director of the Post-Acute COVID-19 Syndrome Center at Stanford University, told us in an email. Vaccines can be life-saving and it is important that we remember their benefits for public health and the broader population as we continue to research and better understand their potential complex effects in subsets of individuals.

The results of the preprint would only potentially (if peer-reviewed and published) be applicable to patients who self-identify as having post-vaccination syndrome, Dr. Alan Kwan, a cardiologist at Cedars-Sinai, told us in an email. It should not be extrapolated to any other groups including all vaccination patients, and does not address any questions of mechanism, or causality.

Dr. Jennifer Frontera, a neurocritical care specialist at NYU Langone Health, expressed doubt that COVID-19 vaccinations caused the symptoms described in the preprint. She described the results of her ownresearchinto neurological events after vaccination, which only showed rare links between the Johnson & Johnson vaccine and neurological conditions. Peoples symptoms are real, right? But they are probably related to something else, she said.

The study participants were all members of an online support and research community for people affected by COVID-19, calledKindred. Krumholz co-founded a company that developed software used in the Kindred platform to help people share their medical records.

The first users of the platform were people with long COVID, Krumholz explained, and the community subsequently was expanded to include those who were reporting a chronic syndrome that they associated with vaccination. He added that the two groups of patients were experiencing very similar symptoms, and the challenges that they were facing were also similar. TheLISTEN study, some of which was described in the preprint, includes both of these groups of patients.

Survey questions prompted the participants to consider whether they had around 100 different health conditions as a result of vaccine injury. The most common problems attributed to vaccination reported in half or more of the participants were exercise intolerance, excessive fatigue, numbness, brain fog, neuropathy, insomnia, palpitations, muscle or body aches, tinnitus or humming in ears, headache, burning sensations, and dizziness.

In this study, individuals who reported [post-vaccination syndrome] after covid-19 vaccination had low health status, high symptom burden, and high psychosocial stress despite trying many treatments, the researchers concluded in the preprint. There is a need for continued investigation to understand and treat this condition.

The researchers ultimately plan to analyze not only data on symptoms and medical history, but also some blood and saliva samples.

We are planning studies that will correlate what people are experiencing with biological signals that may indicate some underlying cause, Krumholz said. There are so many questions. Many of these people have been dismissed by the healthcare system. We are continuing to try to find answers.

Krumholz indicated that the definition of the syndrome is a work in progress. If I were to put forth the definition, I would say that it should be a syndrome that begins within a week of the vaccination and persists for over a month. But it would be important to bring people together, including those who were affected, to develop a definition that is useful and acceptable to those affected.

The definition of post-vaccine syndrome is murky and not yet a formal clinical diagnosis, and it is challenging to know who may fall into this category as the scientific knowledge about post-COVID and post-vaccine effects evolves, Geng said.

As the authors point out, a causal link between vaccination and what is called PVS cannot be established from these data, although the reported temporal relationship between vaccination and symptom onset is suggestive, Katherine Yih, an epidemiologist at Harvard Pilgrim Health Care Institute, told us in an email. However, she added that the lengthy period between vaccination and filling out the survey might make recall and the timing of symptom onset uncertain.

I just dont like people calling something a syndrome, post-vaccination syndrome, Frontera said. I feel like thats unfortunate, because it really kind of implies causality.

Frontera said that the symptoms described in the paper are often associated with treatable mood disorders, like depression or anxiety. She added that the group reported many preexisting health problems and social stressors, including loneliness and isolation.

Frontera referenced her own work on long-term outcomes after severe COVID-19, which involved conducting phone interviews with patients one year after hospitalization. She found that life stressors within the month prior to the phone interview were associated with prolonged COVID-19 symptoms and generally poor outcomes, such as worse depression, fatigue and sleep.

Geng said that the symptoms reported in the study highly overlap with Long COVID. The researchers excluded people from the study who reported that they had long COVID, Geng said, but it is not always easy to know if the self-categorization is correct.

There is no diagnostic test to determine if someone has long COVID, she explained, and people may get COVID-19 and be unaware of it. Around a third of the study participants reported having had COVID-19 at least once. Depending on the extent of their medical evaluation, it is also possible there are other medical conditions that are causing these symptoms that may be missed or not yet diagnosed, Geng said.

The Centers for Disease Control and Prevention and the U.S. Food and Drug Administration have not thus far found evidence of a cluster of chronic symptoms after vaccination similar to those described in the preprint.

The two agencies are aware of reports in the Vaccine Adverse Event Reporting System (VAERS) and in the media of a wide range of long-lasting symptoms following COVID-19 vaccination (such as fatigue, headache, and difficulty concentrating), a CDC spokesperson told us in an email, adding that these symptoms have also been reported withlong COVID.

However, to date, no unusual or unexpected patterns of long-lasting symptoms or health problems following vaccination have been linked to vaccination by COVID-19 vaccine safety monitoring systems, the spokesperson said.

While some of the symptoms described in the preprint such as fatigue, muscle aches and headache overlap with symptomscommonlyexperienced shortly after vaccination, it is not common for these symptoms to become chronic. Data from theclinicaltrialsfor the mRNA COVID-19 vaccines indicate that common post-vaccination symptoms resolved within days on average. Safety monitoring after the COVID-19 vaccine rolloutcontinuedto indicate that vaccine side effects were generally short-lived.

Still, some researchers left open the possibility that there are yet-undetected vaccine adverse events.

I dont want to impugn the surveillance systems used by the CDC but it is possible that they are missing this syndrome, Krumholz said. What I can say for sure is that there are many people who are suffering from a chronic syndrome that is very debilitating and began after the vaccination. It is possible that it is a coincidence but it is important that we follow the science and discover the cause, wherever that leads us, so we can develop strategies to help these people.

Kwan said in an interview that vaccine safety monitoring databases, such as VAERS, are more easily set up to measure things like myocarditis and less set up to measure symptoms like fatigue or the things that were asked in this survey.

He co-authored astudybased on medical records indicating a possible link between COVID-19 vaccination and postural orthostatic tachycardia syndrome, or POTS. POTS symptoms, such as dizziness and palpitations, overlap with those reported in the preprint. Kwans study found that people were more likely to be diagnosed with POTS in the 90 days after vaccination than in the 90 days before vaccination. But it also found a much more pronounced link between POTS and COVID-19,indicatingthat vaccination could still ultimately reduce the risk of POTS even if the link between vaccination and POTS proved to be causal.

I personally believe there are patients out there who had adverse reactions to the vaccine and were likely injured by the vaccine and likely suffer long-term medical symptoms from it, Kwan said. I think its unlikely that its a significant number of patients. It would not discourage me from encouraging people to receive their vaccinations.

Yih co-authored a study using another vaccine safety monitoring system, Vaccine Safety Datalink, to attempt to detect unexpected COVID-19 vaccine adverse events. She said that the study detected a link between the mRNA COVID-19 vaccines and conditions such as muscle aches, headache, malaise, fatigue and palpitations but that its difficult to differentiate known, common short-term side effects from long-term problems.

Specially designed studies focusing on [post-vaccination syndrome] will be needed to more fully characterize and understand this outcome and its relationship with vaccination, she said.

The widespread dissemination of vaccineinformation, misinformation and disinformation can influence peoples experiences of vaccine side effects, complicating the study of peoples experiences after vaccination.

Much as the placebo effect can cause someone to experience improvements simply due to the belief they are receiving a medical intervention, a related phenomenon called the nocebo effect can cause people to experience side effects when they have only received a placebo.

Geng pointed to studies that indicatevaccine hesitancy,negative expectations or negative prior experienceswith vaccination can influence the COVID-19 vaccine side effects people have, which she said may be of interest and have some relevance to this topic at hand.

She also cited astudyexploring vaccine side effects in the placebo arms of the COVID-19 vaccine clinical trials that found that about a third of participants experienced systemic side effects after each dose. The most common side effects were headache and fatigue.

This was a lower rate of side effects than reported in the people who got a vaccine, but nonetheless indicates a substantial nocebo response, the researchers said. They wrote that headache, fatigue, malaise and joint pain seem to have been particularly associated with nocebo.

On the other side of the coin, narratives about vaccines and the prevalence of anti-vaccine sentiments may also marginalize people who experience health problems following vaccination. These people may be lumped into this general anti-vax sentiment, which I dont think a lot of them are, Kwan said.

Kwan added that its important to acknowledge that there are people who may have symptoms or injuries related to vaccine administration, and that there needs to be a space for them within the medical community to receive meaningful and effective care and to be heard.

Editors note: SciChecks articles providing accurate health information and correcting health misinformation are made possible by a grant from the Robert Wood Johnson Foundation. The foundation has no control over FactCheck.orgs editorial decisions, and the views expressed in our articles do not necessarily reflect the views of the foundation.

Getting Your COVID-19 Vaccine. CDC website. Updated 29 Sep 2023.

Selected Adverse Events Reported after COVID-19 Vaccination. CDC website. Updated 12 Sep 2023.

COVID-19 Vaccine Effectiveness Update. CDC website. 31 Aug 2023.

Long COVID or Post-COVID Conditions. CDC website. 20 Jul 2023.

Krumholz, Harlan M. et al. Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization. medRxiv.10 Nov 2023.

Yandell, Kate. COVID-19 Vaccines Save Lives, Are Not More Lethal Than COVID-19. FactCheck.org. 6 Nov 2023.

Krumholz, Harlan. Email to FactCheck.org. 10 Dec 2023.

The Jimmy Dore Show. Its Called Post-Vaccine Syndrome And Its Real! Facebook. 29 Nov 2023.

Fichera, Angelo. Video Doesnt Show Biden Hosting Black Face Skit. FactCheck.org. 17 Jul 2020.

Jones, Brea. FDA-Approved Electronic Pill Isnt Evidence That COVID-19 Vaccine Microchip Conspiracy Is Proven. FactCheck.org. 26 May 2022.

Jones, Brea. Liberal World Order Is Decades-Old Term Misinterpreted by Social Media Posts. FactCheck.org. 8 Jul 2022.

Jones, Brea. Posts Distort Chinese Research Creating Fragment of Monkeypox Viral Genome. FactCheck.org. 29 Jul 2022.

Dr. John Campbell. New syndrome. YouTube. 19 Nov 2023.

Geng, Linda. Email to FactCheck.org. 6 Dec 2023.

Kwan, Alan. Interview and email with FactCheck.org. 5 and 13 Dec 2023.

Frontera, Jennifer. Interview with FactCheck.org. 6 Dec 2023.

Frontera, Jennifer A. et al. Neurological Events Reported after COVID19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System. Annals of Neurology. 2 Mar 2022.

The LISTEN Study. Hugo Health Kindred website. Accessed 15 Dec 2023.

Yih, Katherine. Email with FactCheck.org. 13 Dec 2023.

Frontera, Jennifer A. et al. Life Stressors Significantly Impact Long-Term Outcomes and Post-Acute Symptoms 12-Months after COVID-19 Hospitalization. Journal of the Neurological Sciences. 5 Nov 2022.

Caring for People with Long COVID. CDC website. Updated 28 Sep 2023.

Polack, Fernando P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 31 Dec 2020.

Baden, Lindsey R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 4 Feb 2021.

Rosenblum, Hannah G. et al. Safety of mRNA Vaccines Administered during the Initial 6 Months of the US COVID-19 Vaccination Programme: An Observational Study of Reports to the Vaccine Adverse Event Reporting System and v-Safe. The Lancet Infectious Diseases. 7 Mar 2022.

Kwan, Alan C. et al. Apparent Risks of Postural Orthostatic Tachycardia Syndrome Diagnoses after COVID-19 Vaccination and SARS-Cov-2 Infection. Nature Cardiovascular Research. 12 Dec 2022.

Lovelace Jr., Berkeley. POTS, a Debilitating Heart Condition, Is Linked to Covid and, to a Lesser Degree, Vaccines. NBC News. 12 Dec. 2022.

Yih, W. Katherine et al. A Broad Assessment of Covid-19 Vaccine Safety Using Tree-Based Data-Mining in the Vaccine Safety Datalink. Vaccine. 16 Dec 2022.

MacKrill, Kate. Impact of Media Coverage on Side Effect Reports from the COVID-19 Vaccine. Journal of Psychosomatic Research. 17 Nov 2022.

Hoffman, Yaakov S. G. et al. Vaccine Hesitancy Prospectively Predicts Nocebo Side-Effects Following COVID-19 Vaccination. Scientific Reports. 5 Dec 2022.

Schfer, Ingmar et al. Expectations and Prior Experiences Associated With Adverse Effects of COVID-19 Vaccination. JAMA Network Open. 27 Mar 2023.

Haas, Julia W. et al. Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-Analysis. JAMA Network Open. 18 Jan 2022.

Here is the original post:

Vaccine safety studies indicate serious adverse events are rare - The Washington Informer

COVID-19 vaccine hesitancy: 10 tips for talking with patients – American Medical Association

December 20, 2023

The data is clear: Americans arent getting their updated COVID-19 shots. According to the latest figures from the Centers for Disease Control and Prevention (CDC), just 14% of Americans received the updated COVID-19 vaccine as of Nov. 4.

And its not just COVID-19 vaccines that are lagging. The CDC says just 37.5% of American adults have received their flu shot so far. Uptake of the vaccine that prevents RSV is below par, toowith only 15.9% of those older 60 have received an RSV vaccine.

Physicians can help boost those numbers among the majority of patients who are not implacably opposed to vaccination, but who just have not made the effort or who have some questions.

How we talk about vaccines with patients is very individual and its very personal. That is part of the beauty of the personal relationship with patients. The most important thing is bringing it up and having that chance to talk about it and having that chance to give your advice and your recommendation to the patient. And, of course, being open to their questions, said Frederick M. Chen, MD, MPH, the AMAs chief health and science officer.

People do have a choice. They have a decision to make about it, but part of our job is being there at the right time for them and helping them make those decisions, Dr. Chen added.

Internist Marie T. Brown, MD, the AMA's director of practice redesign, discussed strategies during a recent AMA webinar, "Vaccinations: Roadmap for Success."She also joined infectious disease specialist Constance A. Benson, MD, a professor of medicine and global public health at University of California, San Diego, in discussing tips during anAMA video interview in 2021.

Here are 10 key tips for talking with your patients.

Know you are the most trusted information source

Its not the celebrity doctors or doctors sharing information on social media that patients trust for information. Its their local doctor, according to recent research that a group of about a dozen physicians and other health-related organizations, including the AMA, conducted as part of an effort to mitigate the spread of medical misinformation.

Despite the burnout physicians may feel, data shows they can be effective in countering vaccine misinformation. KFF research has found that a person's own physician is the most trusted source for information on the COVID-19 vaccine, with 85% of respondents holding this belief no matter their gender, sex, ethnicity or political belief.

Tell patients they need to get the vaccine

Adult patients say the second biggest reason they don't get an immunization is that a "doctor hasn't told me I need it," previously published research has shown.

Dr. Chen said: As doctors, we know that, but sometimes we forget we have to actually say it and recommend it.

Get trusted insight from physicians on hot topics in todays health care headlinesdelivered to your inbox.

Understand your patients' concerns

Some patients from historically marginalized racial and ethnic groups may be hesitant because of mistrust in the medical community stemming from their own or loved ones experiences with systemic racism in health care. Physicians should try to build trust, recognizing what has happened so they can then move forward.

Ask why a patient is hesitant

If someone declines the vaccine, you can say, "May I ask why? What have you heard in your community?" It is a less judgmental way to find out what they may be thinking, giving patients the opportunity to give frank voice to concerns they might have while attributing them to others.

Counter any misinformation

People hear and see a lot of misinformation in their social circles and on social media. As a physician, you need to correct any misinformation a patient may give for not getting the vaccine.

Tailor your message

To reach people, no matter their political viewor whether they believe a vaccine is a personal choice or collective responsibilityfocus the discussion on how getting a vaccine can help protect a loved one such as a grandparent, a child or someone who is immunocompromised.

Address patients' fears about side effects

Start a conversation by asking a patient how they felt after their last vaccination. Generally speaking, people tend to have the same reaction they had with the last vaccine, or even a milder reaction than the last one.

Prepare your staff to answer questions

Stay updated with the AMA COVID-19 resource center for physicians, which among other things highlights resources available as part of the Department of Health and Human Services We Can Do This public education campaign to boost confidence in COVID-19 vaccination and reinforce basic prevention measures.

Show your vaccination pride

Everyone in your office who is vaccinated canwear a button or stickershowing they received their updated COVID-19 vaccine, reinforcing to people that the vaccine is safe and that you trust in it.

Tell stories to make impact

The public tends to weigh risks and benefits differently than physicians do, so telling stories that illustrate why the vaccine is important will have a stronger impact on patients.

See the article here:

COVID-19 vaccine hesitancy: 10 tips for talking with patients - American Medical Association

Moderna-Merck vaccine cuts odds of skin cancer recurrence in half, study finds – CBS News

December 16, 2023

A vaccine shows promising results in treating the most deadly form of skin cancer, Moderna and Merck announced on Thursday.

Those with severe melanomas who received the vaccine and Merck's cancer drug Keytruda were 49% less likely to die or have their cancer come back after three years than those who were given only Keytruda, the biotech companies said in a news release.

The findings are based on an ongoing randomized trial involving 157 patients with high-risk stage III/IV melanoma who first had surgery to completely remove cancerous growths. Patients received one milligram of the mRNA vaccine every three weeks for nine doses, and 200 milligrams of Keytruda every three weeks for about a year versus Keytruda alone for approximately a year.

The companies have begun Phase 3 trials of mRNA-4157 with Keytruda for people with stage III and IV melanoma. The Food and Drug Administration earlier this year designated the treatment as a breakthrough therapy in order to expedite the development and review of drugs meant to treat life-threatening diseases.

click to expand

"We look forward to sharing these data with people impacted by the disease and the broader scientific community," Kyle Holen, M.D., Moderna's senior vice president and head of development, therapeutics and oncology, stated.

The results are a vindication of sorts for Moderna's strategy to develop new uses for messenger RNA technology used in its COVID-19 vaccine. Cambridge, Massachusetts-based Moderna said in November it anticipates a steep decline in revenue next year, fueling worries about its capacity to finance multiple product launches planned for 2024 and 2025.

Skin cancer is the most common form of cancer, with melanoma accounting for only about 1% of skin cancer cases in the U.S. That said, it causes a large majority of skin cancer deaths, according to the American Cancer Society. It estimates about 97,610 new melanomas will be diagnosed in the U.S. this year, resulting in 7,990 deaths.

Moderna's stock has cratered this year, falling 50%. On Thursday, its shares shot up 12% in mid-day trading to $87.93.

Rahway, New Jersey-based Merck shares treaded water, down 0.2% at $106.16.

Kate Gibson is a reporter for CBS MoneyWatch in New York.

Read More

Read this article:

Moderna-Merck vaccine cuts odds of skin cancer recurrence in half, study finds - CBS News

As winter virus activity picks up, CDC warns of ‘urgent need’ to boost vaccine coverage – NBC News

December 16, 2023

Not enough Americans are being vaccinated against Covid, the flu and RSV to stem rising numbers of the respiratory illnesses, the Centers for Disease Control and Prevention said Thursday.

The agency issued a health alert to doctors across the country, warning that low vaccination rates amid "ongoing increases in national and international respiratory disease activity" could strain U.S. health care systems in the coming weeks, and called on doctors to encourage their patients to get the shots immediately to protect them for the remainder of the season.

"In the past 4 weeks, hospitalizations among all age groups increased by200% for influenza,51% for Covid-19, and60% for RSV," the CDC said in its health alert. "Currently, the highest respiratory disease activity in the United States is occurring across the southern half of the country, with increasing activity in northern states."

As of Dec. 8, just 17.2% of adults had received the updated Covid shot, according to the CDC. About 40% of children and adults have gotten this year's flu shot. And 15.9% of older adults eligible for the RSV vaccine have received it.

The warning comes as illnesses are increasing among children including an apparent uptick in a rare Covid-related complication called MIS-C, the CDC said. Cases had appeared to drop in recent years.

But from September to mid-December, the CDC received 30 such reports in kids, reflecting a "relative increase" compared with previous months.

RSV is also surging as a key drug in helping to keep babies safe from the virus has been in short supply.

Doctors should not hoard the few doses they have of the drug, called Beyfortus, the CDC said, and instead give all they can now, rather than wait for the situation to possibly worsen later this season. The CDC recommends Beyfortus for babies and toddlers up to 19 months old.

On Thursday, the Biden administration announced that it had worked with drug companies to release an additional 230,000 doses of the drug, expected in January.

The flu is also affecting children: So far this season, 12 children have died, the CDC has reported.

Emergency room visits for cases of pneumonia in children have also increased since September, the CDC said, though the number of those illnesses is what would normally be expected during cold and flu season, and is no more severe than usual.

According to the CDC, everyone 6 months and older should get the flu and Covid vaccines. Some people, depending on their previous vaccination status or health, might need two shots this season.

Research shows that it is safe to get both shots at the same time.

New this year, people age 60 and older have access to a vaccine to help prevent RSV. The vaccine is also recommended for women in a specific window of pregnancy: 32 through 36 weeks gestation.

People can find where Covid and flu vaccines are available near them at Vaccines.gov.

Erika Edwards is a health and medical news writer and reporter for NBC News and "TODAY."

Go here to see the original:

As winter virus activity picks up, CDC warns of 'urgent need' to boost vaccine coverage - NBC News

Page 126«..1020..125126127128..140150..»